þ
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
¨
|
TRANSITION REPORT PURSUANT TO 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Delaware
|
11-1719724
|
(State or Other Jurisdiction of
|
(I.R.S. Employer Identification No.)
|
Incorporation or Organization)
|
Large accelerated filer
|
o
|
Non-accelerated filer
|
o (Do not check if a smaller reporting company)
|
Accelerated filer
|
o
|
Smaller reporting company
|
þ
|
Page No. | |
Part I. FINANCIAL INFORMATION
|
|
Part II. OTHER INFORMATION
|
|
UNITED-GUARDIAN, INC.
STATEMENTS OF INCOME
(UNAUDITED)
|
||||||||
THREE MONTHS ENDED
MARCH 31,
|
||||||||
2012
|
2011
|
|||||||
Net sales
|
$ | 3,888,692 | $ | 3,642,049 | ||||
Costs and expenses:
|
||||||||
Cost of sales
|
1,539,840 | 1,460,590 | ||||||
Operating expenses
|
602,863 | 521,146 | ||||||
Total costs and expenses
|
2,142,703 | 1,981,736 | ||||||
Income from operations
|
1,745,989 | 1,660,313 | ||||||
Other income:
|
||||||||
Investment income
|
69,591 | 71,323 | ||||||
Gain (loss) on sale of asset
|
2,750 | (5,253 | ) | |||||
Total other income
|
72,341 | 66,070 | ||||||
Income before income taxes
|
1,818,330 | 1,726,383 | ||||||
Provision for income taxes
|
589,700 | 560,200 | ||||||
Net income
|
$ | 1,228,630 | $ | 1,166,183 | ||||
|
||||||||
Earnings per common share (Basic and Diluted)
|
$ | 0.27 | $ | 0.25 | ||||
Weighted average shares – basic and diluted
|
4,596,439 | 4,596,439 |
UNITED-GUARDIAN, INC.
|
||||||||
STATEMENTS OF COMPREHENSIVE INCOME
|
||||||||
(UNAUDITED)
|
||||||||
THREE MONTHS ENDED
MARCH 31,
|
||||||||
|
2012
|
2011
|
||||||
Net income
|
$ | 1,228,630 | $ | 1,166,183 | ||||
Other comprehensive income:
|
||||||||
Unrealized gain on marketable securities during period
|
95,171 | 23,556 | ||||||
Income tax expense related to other comprehensive income
|
32,987 | 8,163 | ||||||
Other comprehensive income, net of tax
|
62,184 | 15,393 | ||||||
Comprehensive income
|
$ | 1,290,814 | $ | 1,181,576 |
ASSETS
|
MARCH 31,
|
DECEMBER 31,
|
||||||
2012
|
2011
|
|||||||
(UNAUDITED)
|
|
|||||||
Current assets:
|
||||||||
Cash and cash equivalents
|
$ | 1,582,188 | $ | 1,090,974 | ||||
Marketable securities
|
10,883,539 | 9,295,755 | ||||||
Accounts receivable, net of allowance for doubtful accounts of $18,000 at March 31, 2012 and December 31, 2011
|
1,529,393 | 1,653,440 | ||||||
Inventories (net)
|
1,256,575 | 1,467,434 | ||||||
Prepaid expenses and other current assets
|
167,258 | 163,034 | ||||||
Prepaid income taxes
|
--- | 78,613 | ||||||
Deferred income taxes
|
223,546 | 223,546 | ||||||
Total current assets
|
15,642,499 | 13,972,796 | ||||||
Property, plant and equipment:
|
||||||||
Land
|
69,000 | 69,000 | ||||||
Factory equipment and fixtures
|
3,740,393 | 3,694,379 | ||||||
Building and improvements
|
2,716,516 | 2,714,780 | ||||||
Waste disposal plant
|
133,532 | 133,532 | ||||||
Total property, plant and equipment
|
6,659,441 | 6,611,691 | ||||||
Less: Accumulated depreciation
|
5,404,609 | 5,366,204 | ||||||
Total property, plant and equipment, net
|
1,254,832 | 1,245,487 | ||||||
Other assets
|
28,254 | 37,672 | ||||||
TOTAL ASSETS
|
$ | 16,925,585 | $ | 15,255,955 |
UNITED-GUARDIAN, INC.
BALANCE SHEETS
(continued)
|
LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
MARCH 31,
|
DECEMBER 31,
|
|||||||
2012
|
2011
|
|||||||
Current liabilities:
|
(UNAUDITED)
|
|
||||||
Accounts payable
|
$ | 127,506 | $ | 400,389 | ||||
Accrued expenses
|
794,129 | 676,959 | ||||||
Income taxes payable
|
501,542 | --- | ||||||
Total current liabilities
|
1,423,177 | 1,077,348 | ||||||
Deferred income taxes
|
97,565 | 64,578 | ||||||
Stockholders’ equity:
|
||||||||
Common stock $.10 par value, authorized, 10,000,000 shares; 4,596,439 shares issued and outstanding at March 31, 2012 and December 31, 2011.
|
459,644 | 459,644 | ||||||
Accumulated other comprehensive loss
|
96,796 | 34,612 | ||||||
Retained earnings
|
14,848,403 | 13,619,773 | ||||||
Total stockholders’ equity
|
15,404,843 | 14,114,029 | ||||||
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY
|
$ | 16,925,585 | $ | 15,255,955 |
UNITED-GUARDIAN, INC.
STATEMENTS OF CASH FLOWS
(UNAUDITED)
|
||||||||
THREE MONTHS ENDED
|
||||||||
MARCH 31,
|
||||||||
2012
|
2011
|
|||||||
Cash flows from operating activities:
|
||||||||
Net income
|
$ | 1,228,630 | $ | 1,166,183 | ||||
Adjustments to reconcile net income to net cash provided by operating activities:
|
||||||||
Depreciation and amortization
|
66,943 | 57,269 | ||||||
Realized loss on sale of investments
|
6,489 | --- | ||||||
Realized (gain) loss on sale of asset
|
(2,750 | ) | 5,253 | |||||
Increase (decrease) in cash resulting from changes in operating assets and liabilities:
|
||||||||
Accounts receivable
|
124,047 | (653,340 | ) | |||||
Inventories
|
210,859 | 153,680 | ||||||
Prepaid expenses and other current assets
|
(4,224 | ) | 21,352 | |||||
Accounts payable
|
(272,883 | ) | 180,313 | |||||
Accrued expenses and taxes payable
|
697,325 | 492,354 | ||||||
Net cash provided by operating activities
|
2,054,436 | 1,423,064 | ||||||
Cash flows from investing activities:
|
||||||||
Acquisition of property, plant and equipment
|
(66,870 | ) | (32,572 | ) | ||||
Proceeds from sales of assets
|
2,750 | 15,154 | ||||||
Proceeds from sale of marketable securities
|
80,744 | --- | ||||||
Purchase of marketable securities
|
(1,579,846 | ) | (356,598 | ) | ||||
Net cash used in investing activities
|
(1,563,222 | ) | (374,016 | ) | ||||
|
||||||||
Net increase in cash and cash equivalents
|
491,214 | 1,049,048 | ||||||
Cash and cash equivalents at beginning of period
|
1,090,974 | 1,514,589 | ||||||
Cash and cash equivalents at end of period
|
$ | 1,582,188 | $ | 2,563,637 |
1.
|
Nature of Business
|
2.
|
Basis of Presentation
|
3.
|
Stock-Based Compensation
|
|
As of March 31, 2012, the Company had no share-based awards outstanding and exercisable and did not grant any options during the three months ended March 31, 2012.
|
|
As of March 31, 2012, there was no remaining unrecognized compensation cost related to the non-vested share-based compensation arrangements granted under the Company's plans.
|
|
The Company did not record any stock-based compensation expense during the three-month periods ended March 31, 2012 and 2011.
|
|
The Company did not receive any proceeds from the exercise of options during the three months ended March 31, 2012 and 2011.
|
4.
|
Recent Accounting Pronouncements
|
5.
|
Investments
|
·
|
Level 1 – inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
|
·
|
Level 2 – inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially for the full term of the financial statement.
|
·
|
Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value measurement.
|
March 31, 2012 | Cost | Fair Value |
Unrealized
Gain (Loss)
|
|||||||||
Available for sale:
|
||||||||||||
U.S. treasury and agencies:
|
||||||||||||
Maturities within 1 year
|
$ | 249,137 | $ | 231,657 | $ | (17,480 | ) | |||||
|
||||||||||||
Corporate bonds
|
||||||||||||
Maturities within 1 year
|
185,747 | 171,757 | (13,990 | ) | ||||||||
Maturities after 1 year through 5 years
|
203,920 | 203,150 | (770 | ) | ||||||||
Total corporate bonds
|
389,667 | 374,907 | (14,760 | ) | ||||||||
Fixed income mutual funds
|
9,841,477 | 10,002,617 | 161,140 | |||||||||
Equity and other mutual funds
|
255,114 | 274,358 | 19,244 | |||||||||
$ | 10,735,395 | $ | 10,883,539 | $ | 148,144 |
December 31, 2011 | Cost | Fair Value |
Unrealized
Gain (Loss)
|
|||||||||
Available for sale:
|
||||||||||||
U.S. treasury and agencies
|
||||||||||||
Maturities within 1 year
|
$ | 249,137 | $ | 234,388 | $ | (14,749 | ) | |||||
|
||||||||||||
Corporate bonds:
|
||||||||||||
Mature within 1 year
|
267,251 | 247,719 | (19,532 | ) | ||||||||
Maturities after 1 year through 5 years
|
203,920 | 195,899 | (8,021 | ) | ||||||||
Total corporate bonds
|
471,171 | 443,618 | (27,553 | ) | ||||||||
Fixed income mutual funds
|
8,268,624 | 8,372,216 | 103,592 | |||||||||
Equity and other mutual funds
|
253,850 | 245,533 | (8,317 | ) | ||||||||
$ | 9,242,782 | $ | 9,295,755 | $ | 52,973 |
6.
|
Inventories
|
March 31,
|
December 31,
|
|||||||
2012
|
2011
|
|||||||
Inventories consist of the following:
|
||||||||
Raw materials and work in process
|
$ | 548,356 | $ | 470,532 | ||||
Finished products
|
708,219 | 996,902 | ||||||
$ | 1,256,575 | $ | 1,467,434 |
7.
|
Supplemental Financial Statement Information
|
|
Research and development expenses amounted to $146,342 and $127,271 for the first quarters of 2012 and 2011, respectively, and are included in operating expenses.
|
|
There were no dividends paid in the first quarters of 2012 and 2011.
|
8.
|
Income Taxes
|
|
The Company’s tax provision is based on its estimated annual effective tax rate. The Company continues to fully recognize its tax benefits, which are offset by a valuation allowance to the extent that it is more likely than not that the deferred tax assets will not be realized. As of December 31, 2011 and March 31, 2012, the Company did not have any unrecognized tax benefits.
|
|
The Company files consolidated Federal income tax returns in the United States with its inactive subsidiary, and separate income tax returns in New York State. The Company is subject to examination by the Internal Revenue Service and by New York State for years 2008 through 2011.
|
9.
|
Comprehensive Income
|
|
Accumulated other comprehensive income comprises unrealized gains and losses on marketable securities net of the related tax effect.
|
10.
|
Defined Contribution Plan
|
11.
|
Related Party Transactions
|
Accrued Expenses | ||||||||
March 31,
|
December 31,
|
|||||||
2012
|
2011
|
|||||||
Accrued bonuses
|
$ | 300,000 | $ | 200,000 | ||||
Accrued distribution fees
|
193,904 | 191,171 | ||||||
Payroll and related expenses
|
177,475 | 80,986 | ||||||
Other
|
122,750 | 204,802 | ||||||
$ | 794,129 | $ | 676,959 |
Item 2.
|
Management's Discussion and Analysis of Financial Condition and Results of Operations
|
|
Forward-looking statements involve inherent risks and uncertainties, and important factors (many of which are beyond our control) could cause actual results to differ materially from those set forth in the forward-looking statements. In addition to those specific risks and uncertainties set forth in the Company's reports currently on file with the SEC, some other factors that may affect the future results of operations of the Company are: the development of products that may be superior to those of the Company; changes in the quality or composition of the Company's products; lack of market acceptance of the Company's products; the Company's ability to develop new products; general economic or industry conditions; intellectual property rights; changes in interest rates; new legislation or regulatory requirements; conditions of the securities markets; the Company's ability to raise capital; changes in accounting principles, policies or guidelines; financial or political instability; acts of war or terrorism; and other economic, competitive, governmental, regulatory and technical factors that may affect the Company's operations, products, services and prices.
|
|
Accordingly, results actually achieved may differ materially from those anticipated as a result of such forward-looking statements, and those statements speak only as of the date they are made. The Company does not undertake, and specifically disclaims, any obligation to update any forward-looking statements to reflect events or circumstances occurring after the date of such statements.
|
|
The Company is a Delaware corporation that conducts research, product development, manufacturing and marketing of cosmetic ingredients, personal and health care products, pharmaceuticals, and specialty industrial products. All of the products that the Company manufactures, with the exception of its RENACIDIN IRRIGATION® (“RENACIDIN”), are produced at its facility in Hauppauge, New York, and are marketed through marketing partners, distributors, wholesalers, direct advertising, mailings, and trade exhibitions. Its most important personal care product line is its LUBRAJEL® line of water-based moisturizing and lubricating gels. It also sells two pharmaceutical products for urological uses. Those products are sold primarily through the major drug wholesalers, which in turn sell the products to pharmacies, hospitals, nursing homes and other long-term care facilities, and to government agencies, primarily the Veteran's Administration.
|
|
While the Company does have competition in the marketplace for some of its products, many of its products are either unique in their field or have some unique characteristics, and therefore are not in direct competition with the products of other pharmaceutical, specialty chemical, or health care companies. Many of the Company’s products are manufactured using patented or proprietary processes. The Company’s research and development department is actively working on the development of new products to expand the Company's line of personal care and performance products.
|
|
The Company recognizes revenue when products are shipped, title and risk of loss pass to the customers, persuasive evidence of a sales arrangement exists, and collections are reasonably assured. An allowance for returns, based on historical experience, is taken as a reduction of sales within the same period the revenue is recognized.
|
|
The Company has been issued many patents and trademarks and intends, whenever possible, to make efforts to obtain patents in connection with its product development program.
|
|
As disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011, the discussion and analysis of the Company’s financial condition and results of operations are based on its financial statements, which have been prepared in conformity with U.S. generally accepted accounting principles. The preparation of those financial statements required the Company to make estimates and assumptions that affect the carrying value of assets, liabilities, revenues and expenses reported in those financial statements. Those estimates and assumptions can be subjective and complex, and consequently actual results could differ from those estimates and assumptions. The Company’s most critical accounting policies relate to revenue recognition, concentration of credit risk, inventory, patents, and income taxes. Since December 31, 2011, there have been no significant changes to the assumptions and estimates related to those critical accounting policies.
|
|
The following discussion and analysis covers material changes in the financial condition of the Company since the year ended December 31, 2011, and a comparison of the results of operations for the three months ended March 31, 2012 and March 31, 2011. This discussion and analysis should be read in conjunction with "Management's Discussion and Analysis or Plan of Operation" included in the Company's Annual Report on Form 10-K for the year ended December 31, 2011.
|
|
Sales
|
(a)
|
Personal care products: For the first quarter of 2012 the Company’s gross sales of personal care products increased by $125,653 (5.0%) when compared with the same period in 2011. This increase was due to an increase of $141,324 (6.8%) in sales to the Company's largest marketing partner for the first quarter of 2012 when compared with the same period in 2011. The Company believes that the overall increase in personal care product sales was due to a number of factors, including an increase in demand for the Company's products, the replenishment of low inventory levels of certain products by the Company’s largest marketing partner, and the timing of customer orders.
|
(b)
|
Pharmaceuticals: Gross sales of pharmaceuticals increased by $395,014 (138.9%) in the first quarter of 2012 compared with the same period in 2011. The increase was primarily due to increased sales of RENACIDIN, which had normal production and availability in the first quarter of 2012 compared with limited availability in the first quarter of 2011. The limited availability in the first quarter of 2011 was due to the temporary curtailment of production by the Company’s sole supplier of RENACIDIN from late 2010 until early 2011, due to regulatory issues unrelated to RENACIDIN. There were no such production issues in the first quarter of 2012.
|
(c)
|
Medical (non-pharmaceutical) products: Gross sales of the Company’s medical products decreased $242,131 (26.9%) for the first quarter of 2012 when compared with the same period in 2011. The Company believes the decrease was primarily due to the timing of customer orders.
|
(d)
|
Industrial and other products: Sales of the Company's industrial products, as well as other miscellaneous products, decreased by $7,230 (25.1%) for the first quarter of 2012 compared with the same period in 2011.
|
|
Cost of Sales
|
|
Working capital increased by $1,323,874 to $14,219,322 at March 31, 2012 from $12,895,448 at December 31, 2011. The increase in working capital is primarily due to an increase in marketable securities. The current ratio decreased to 11.0 to 1 at March 31, 2012 from 13.0 to 1 at December 31, 2011. The decrease in the current ratio was primarily due to the effect of an increase in income taxes payable.
|
|
During the three-month period ended March 31, 2012, the average period of time that an account receivable was outstanding was approximately 37 days. The average period of time that an account receivable was outstanding during the three-month period ended March 31, 2011 was 35 days. The increase was mainly due to a few customers who were paying more slowly than normal during the three-month period ended March 31, 2012.
|
|
The Company believes that its working capital is and will continue to be sufficient to support its operating requirements for at least the next twelve months. The Company does not expect to incur any significant capital expenditures for the remainder of 2012.
|
|
The Company generated cash from operations of $2,054,436 and $1,423,064 for the three months ended March 31, 2012 and March 31, 2011, respectively. The increase in cash was primarily due to an increase in accrued expenses and taxes payable, and a decrease in accounts receivable.
|
|
Cash used in investing activities for the three-month period ended March 31, 2012 was $1,563,222, while cash used in investing activities for the three-month period ending March 31, 2011 was $374,016. This decrease in cash was primarily due to an increase in the amount of marketable securities purchased in the first quarter of 2012 compared with the first quarter of 2011.
|
|
The Company has no off-balance sheet transactions that have, or are reasonably likely to have, a current or future effect on the Company’s financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.
|
|
The information to be reported under this item is not required of smaller reporting companies.
|
(a)
|
DISCLOSURE CONTROLS AND PROCEDURES
|
(b)
|
CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING
|
ITEM 1.
|
LEGAL PROCEEDINGS
|
ITEM 1A.
|
RISK FACTORS
|
ITEM 2.
|
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.
|
ITEM 3.
|
DEFAULTS UPON SENIOR SECURITIES
|
ITEM 4.
|
MINE SAFETY DISCLOSURES
|
ITEM 5.
|
OTHER INFORMATION
|
31.1
|
Certification of Kenneth H. Globus, President and Principal Executive Officer of the Company, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
31.2
|
Certification of Robert S. Rubinger, Chief Financial Officer of the Company, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
32
|
Certifications of Principal Executive Officer and Chief Financial Officer of the Company, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|